Merck & Co Inc (MRK)

MRK on New York Consolidated

57.12USD
6 Mar 2015
Change (% chg)

$-0.86 (-1.48%)
Prev Close
$57.98
Open
$57.85
Day's High
$57.87
Day's Low
$57.08
Volume
3,798,938
Avg. Vol
11,002,873
52-wk High
$63.62
52-wk Low
$52.49

MRK

Chart for MRK

About

Merck & Co., Inc., is a health care company. The Company delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures. The Company’s operations are principally managed on a products basis and are... (more)

Overall

Beta: 0.32
Market Cap(Mil.): $166,747.59
Shares Outstanding(Mil.): 2,850.87
Dividend: 0.45
Yield (%): 3.08

Financials

  MRK Industry Sector
P/E (TTM): 14.26 38.98 40.20
EPS (TTM): 4.10 -- --
ROI: -- 17.01 16.34
ROE: -- 17.52 17.27
Search Stocks

Guinea to start final trials of Ebola vaccines this week

LONDON/GENEVA - Final stage trials of an Ebola vaccine being developed by Merck and NewLink Genetics will begin in Guinea on March 7, the World Health Organization said on Thursday.

05 Mar 2015

UPDATE 2-Guinea to start final trials of Ebola vaccines this week

* WHO says effective Ebola shot could be a "game-changer" (Adds details of "ring vaccination" plans, quotes)

05 Mar 2015

Merck-NewLink Ebola vaccine Phase III trial to start March 7

GENEVA, March 5 - Merck & Co and NewLink Genetics Corp's Ebola vaccine will begin a Phase III trial in Guinea on March 7, the final stage of testing, the World Health Organization said on Thursday.

05 Mar 2015

UPDATE 1-Biosimilar copies of blockbuster drug launch in major EU markets

* Biosimilars expected to disrupt market for biotech medicines (Adds detail on price discount, paragraph 7)

25 Feb 2015

Biosimilar copies of blockbuster drug launch in major EU markets

* Biosimilars expected to disrupt market for biotech medicines

25 Feb 2015

Ex-Merck analyst pleads guilty to U.S. insider trading charges

NEW YORK - A former Merck & Co Inc finance analyst pleaded guilty on Thursday to participating in an insider trading scheme in which he passed tips about potential pharmaceutical mergers to a friend who worked at Bank of New York Mellon Corp.

19 Feb 2015

Ex-Merck analyst pleads guilty to U.S. insider trading charges

NEW YORK, Feb 19 - A former Merck & Co Inc finance analyst pleaded guilty on Thursday to participating in an insider trading scheme in which he passed tips about potential pharmaceutical mergers to a friend who worked at Bank of New York Mellon Corp.

19 Feb 2015

Low rates, M&A spur flood of pharma debt deals

NEW YORK, Feb 5 (IFR) - Merck & Co's US$8bn jumbo bond is just the tip of the iceberg of debt supply from the healthcare sector in the months ahead with brand names like Novartis and Pfizer set to compete for investor cash.

05 Feb 2015

US STOCKS-Wall St ends lower with oil prices, renewed Greece worries

* Indexes: Dow up 0.04 pct, S&P down 0.4 pct, Nasdaq down 0.2 pct (Updates to close)

04 Feb 2015

Merck says hepatitis C treatment to lose "breakthrough" status

- Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.

04 Feb 2015

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Sadif Analytics Prime
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks